Download App

Log in to access Online Inquiry
Company Overview More
Cinda Biopharmaceutical is an investment holding company mainly engaged in biopharmaceuticals. The company and its subsidiaries are engaged in the research and development of antibody and protein pharmaceutical products, drug sales and distribution, as well as providing consulting and R & D services. The company's main product is Dabeshu (Xindirizumab injection), which is used to treat relapsed or refractory classical Hodgkin's lymphoma. The company's products also include adamumab bioanalogue IBI-303, which is used to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. Bevacizumab bioanalogue IBI-305 is used in the treatment of metastatic colorectal cancer and advanced, metastatic or recurrent non-small cell lung cancer (NSCLC). Rituximab bioanalogue IBI-301 is used in the treatment of non-Hodgkin's lymphoma and chronic lymphoblastic leukemia. The company's products are used in the fields of oncology, metabolism, immunology and fundus diseases.
CEO: Dechao Yu
Market: Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

01801 INNOVENT BIO
21.600+0.550+2.61%
YOY
Do not show
Hide blank lines
(FY)2021/12/31(Q6)2021/06/30(FY)2020/12/31(Q6)2020/06/30
Assets
Current assets
Inventory
90.92% 1.35B 135.83% 1.1B 96.78% 705.66M 101.72% 467.14M
Accounts receivable
103.71% 968.41M 165.36% 1B 91.8% 475.38M 111.72% 377.77M
Advance deposits and other receivables
29.63% 213.26M 35.97% 164.4M 8.5% 164.52M -13.4% 120.91M
Cash and equivalents
7.9% 8.38B 140.95% 11.16B 83.43% 7.76B 35.04% 4.63B
Special items of current assets
80.48% 644.85M -- -- -23.11% 357.3M 2750.42% 1.56B
Total current assets
22.02% 11.55B 87.54% 13.43B 73.53% 9.47B 76.88% 7.16B
Non-current assets
Property, plant and equipment
70% 2.69B 44.52% 2.01B 17.79% 1.58B 19.36% 1.39B
Advance payment
5.01% 285.91M 602.56% 395.91M 220.9% 272.28M -11.89% 56.35M
Intangible assets
2266.88% 772.19M 175.27% 96.91M -- 32.63M -- 35.21M
Other illiquid assets
1552.06% 213.81M 2189.67% 45.43M 552.32% 12.94M -- 1.98M
Special items of non-current assets
56.08% 727.97M 54.86% 474.28M 35.78% 466.39M -5.97% 306.27M
Total non-current assets
98.15% 4.69B 68.78% 3.02B 33.42% 2.37B 15.16% 1.79B
Total assets
37.25% 16.24B 83.79% 16.46B 63.68% 11.83B 59.75% 8.95B
Liabilities
Current liabilities
Accounts payable
61.71% 195.05M 41.45% 277.33M 43.13% 120.62M 224.65% 196.07M
Tax payable
-- 60.59M -- -- -- -- -- --
Other payables and accrued expenses
110.72% 2.05B 121.87% 1.37B 10.01% 973.63M 10.89% 617.13M
Bank loans and overdrafts
43.14% 365M 153.42% 370M 1400% 255M 1227.27% 146M
Financial lease liabilities-current liabilities
37.85% 22.27M -3.32% 14.94M 3.9% 16.16M 118.78% 15.45M
Special items of current liabilities
195.17% 355.51M 90.71% 210.24M 188.64% 120.44M 186.38% 110.24M
Total current liabilities
105.27% 3.05B 106.63% 2.24B 42.38% 1.49B 61.09% 1.08B
Net current assets
6.52% 8.5B 84.13% 11.19B 80.89% 7.98B 80.03% 6.08B
Total assets less current liabilities
27.49% 13.19B 80.64% 14.21B 67.27% 10.35B 59.57% 7.87B
Non-current liabilities
Long-term bank loan
118.69% 2.02B 85.14% 1.47B 14.5% 925.18M 0.25% 793M
Financial lease liabilities-non-current liabilities
744.25% 86.39M -80.93% 3.13M -58.3% 10.23M 12.2% 16.4M
Deferred income-non-current liabilities
543.27% 294.77M 196.03% 58.51M 177.41% 45.82M 31.82% 19.77M
Investment contract liabilities-non-current liabilities
-22.04% 458.51M -- -- -- 588.14M -- --
Special items of non-current liabilities
-- 342K 22.68% 779.74M -- -- 9.11% 635.57M
Total non-current liabilities
82.45% 2.86B 57.67% 2.31B 9.68% 1.57B 4.39% 1.46B
Total liabilities
93.55% 5.91B 78.51% 4.55B 23.47% 3.06B 22.78% 2.55B
Total assets less total liabilities
17.66% 10.33B 85.89% 11.91B 84.6% 8.78B 81.51% 6.4B
Total equity and non-current liabilities
27.49% 13.19B 80.64% 14.21B 67.27% 10.35B 59.57% 7.87B
Equity
Share capital
4.12% 101K 7.53% 100K 11.49% 97K 17.72% 93K
Reserve
17.66% 10.33B 85.89% 11.91B 84.6% 8.78B 81.51% 6.4B
Legal reserve
17.66% 10.33B 85.89% 11.91B 84.6% 8.78B 81.51% 6.4B
Shareholders' Equity
17.66% 10.33B 85.89% 11.91B 84.6% 8.78B 81.51% 6.4B
Total equity
17.66% 10.33B 85.89% 11.91B 84.6% 8.78B 81.51% 6.4B
Total equity and total liabilities
37.25% 16.24B 83.79% 16.46B 63.68% 11.83B 59.75% 8.95B
Currency Unit
CNYCNYCNYCNY
Accounting Standards
IASIASIASIAS
Audit Opinions
Unqualified Opinion--Unqualified Opinion--
Auditor
Deloitte Guan Huang Chen Fang Accountants--Deloitte Guan Huang Chen Fang Accountants--

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%